

Reference



- [1] Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet* 2016; 388(10049):1081-8.
- [2] Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024.
- [3] Global health sector strategies on viral hepatitis, 2016-2021. Geneva: World Health Organization; 2016.
- [4] Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: World Health Organization; 2022.
- [5] Chang WK, Yeoh EK. Hepatitis B infection in Hong Kong: a serological study of a Chinese population. *J Hong Kong Med Assoc* 1985; 37:27-30.
- [6] Kwan LC, Ho YY, Lee SS. The declining HBsAg carriage rate in pregnant women in Hong Kong. *Epidemiol Infect* 1997; 119:281-3.
- [7] Thematic Report on Viral Hepatitis (Population Health Survey 2020-22). Hong Kong: Department of Health; 2023.
- [8] Wong NS, Chan DP, Chan CP, et al. Point-of-care hepatitis C reflex testing and treatment referral in methadone clinic settings in Hong Kong—a pilot study. *IJID Reg* 2022; 5:8-12.
- [9] Mak LY, To WP, Tsui V, et al. Pilot model of hepatitis C virus micro-elimination in high-risk populations in Hong Kong: barriers and facilitators. *Int J Drug Policy* 2024;132: 104568.
- [10] Surveillance of Viral Hepatitis in Hong Kong - 2022 Report. Hong Kong: Department of Health; 2023.
- [11] Hong Kong Cancer Registry, Hospital Authority. (<https://www3.ha.org.hk/cancereg/>, accessed 13 November 2025)
- [12] Yuen MF, Hou JL, Chutaputti A, et al. Hepatocellular carcinoma in the Asia Pacific Region. *J Gastroenterol Hepatol* 2009; 24(3): 346-53.
- [13] Hong Kong Viral Hepatitis Action Plan 2020 - 2024. Hong Kong: The Government of the Hong Kong Special Administrative Region; 2020.
- [14] Prevention & Control of Viral Hepatitis Infection: Framework for Global Action. Geneva: World Health Organization; 2012.
- [15] Manual for the development and assessment of national viral hepatitis plans: a provisional document. Geneva: World Health Organization; 2015.

- [16] Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: World Health Organization; 2016.
- [17] Consolidated guidelines on person-centred viral hepatitis strategic information: using data to support country scale-up of hepatitis prevention, diagnosis and treatment services. Geneva: World Health Organization; 2024.
- [18] Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus. Geneva: World Health Organization; 2021.
- [19] World Health Organization. Prevention, Global Hepatitis Programme (<https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/prevention>, accessed 20 January 2025)
- [20] Hui VW, Cheung AC, Yip AC, et al. A pilot integrated model nurse clinic increases the uptake of antiviral treatment for the prevention of mother-to-child transmission of HBV. *Liver Int* 2024; 44(10):2583-91.
- [21] Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020.
- [22] Recommendations on the management and postexposure prophylaxis of needlestick injury or mucosal contact to HBV, HCV and HIV. Hong Kong; Department of Health; 2014.
(https://www.chp.gov.hk/files/pdf/recommendations_on_postexposure_management_and_prophylaxis_of_needlestick_injury_or_mucosal_contact_to_hbv_hcv_and_hiv_en_r.pdf, accessed 20 January 2025)
- [23] Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022.
- [24] Martin NK, Vickerman P, Dore GJ, et al. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. *Current opinion in HIV and AIDS* 2015; 10(5):374-80.
- [25] Pitcher AB, Borquez A, Skaathun B, et al. Mathematical modeling of hepatitis C virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. *J Theor Biol* 2019; 481:194-201.
- [26] WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.
- [27] Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.

- [28] Guidelines for the screening care and treatment of persons with chronic hepatitis C infection, Updated version, April 2016. Geneva: World Health Organization; 2016.
- [29] Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018.
- [30] Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva: World Health Organization; 2022.
- [31] Lai JC, Ho AH, Wu CW, et al. HCV elimination in Hong Kong - Non-government organisation (NGO) activities. *Glob Health Med* 2021;3(5):283-7.
- [32] Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatology* 2013; 58(4):1215-24.
- [33] Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *Lancet* 2016; 388(10049):1089-102.
- [34] Ahmadi Gharaei H, Fararouei M., Mirzazadeh A, et al. The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis. *Infect Dis Poverty* 2021; 10:93.
- [35] Hong Kong Correctional Services - Annual Review 2023. Hong Kong: Correctional Services Department; 2024.
(<https://www.csd.gov.hk/annualreview/2023/web/en/chapter/3>, accessed 20 January 2025)
- [36] Mak L, Hui R, Fung J, et al. Novel use of point-of-care hepatitis C virus RNA test for rapid confirmation of sustained virological response after direct acting antivirals among prisoners in Hong Kong. *Hepatol Int* 2025; 19 (Suppl 1):S547.
- [37] Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol* 2023; 8(10):879-907.
- [38] Wong NS, Wong B, Poon CM, et al. Achievability of the impact targets for HCV elimination in people who inject drugs by 2030 in Hong Kong. *Int J Infect Dis* 2025; 152 Suppl: 107482.